Kancera Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Kancera's earnings have been declining at an average annual rate of -10.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 80.9% per year.
Key information
-10.1%
Earnings growth rate
26.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -80.9% |
Return on equity | -136.1% |
Net Margin | n/a |
Next Earnings Update | 17 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kancera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -65 | 8 | 58 |
30 Sep 23 | 0 | -60 | 8 | 53 |
30 Jun 23 | 0 | -61 | 9 | 52 |
31 Mar 23 | 0 | -58 | 8 | 50 |
31 Dec 22 | 0 | -52 | 7 | 46 |
30 Sep 22 | 0 | -51 | 6 | 47 |
30 Jun 22 | 0 | -52 | 4 | 49 |
31 Mar 22 | 0 | -49 | 5 | 45 |
31 Dec 21 | 0 | -46 | 4 | 43 |
30 Sep 21 | 0 | -45 | 6 | 41 |
30 Jun 21 | 0 | -44 | 6 | 39 |
31 Mar 21 | 0 | -38 | 5 | 38 |
31 Dec 20 | 0 | -40 | 6 | 39 |
30 Sep 20 | 0 | -35 | 4 | 35 |
30 Jun 20 | 0 | -34 | 4 | 34 |
31 Mar 20 | 0 | -40 | 8 | 34 |
31 Dec 19 | 3 | -36 | 7 | 35 |
30 Sep 19 | 4 | -41 | 8 | 41 |
30 Jun 19 | 3 | -44 | 8 | 45 |
31 Mar 19 | 3 | -41 | 6 | 44 |
31 Dec 18 | 0 | -46 | 5 | 45 |
30 Sep 18 | 0 | -46 | 4 | 47 |
30 Jun 18 | 0 | -52 | 5 | 51 |
31 Mar 18 | 0 | -59 | 5 | 59 |
31 Dec 17 | 0 | -56 | 5 | 56 |
30 Sep 17 | 0 | -51 | 5 | 46 |
30 Jun 17 | 0 | -39 | 4 | 36 |
31 Mar 17 | 0 | -27 | 4 | 23 |
31 Dec 16 | 0 | -22 | 3 | 19 |
30 Sep 16 | 0 | -22 | 5 | 22 |
30 Jun 16 | 0 | -20 | 5 | 20 |
31 Mar 16 | 0 | -20 | 5 | 20 |
31 Dec 15 | 0 | -20 | 5 | 20 |
30 Sep 15 | 0 | -19 | 3 | 16 |
30 Jun 15 | 0 | -18 | 3 | 16 |
31 Mar 15 | 0 | -17 | 3 | 14 |
31 Dec 14 | 0 | -16 | 3 | 14 |
30 Sep 14 | 2 | -13 | 3 | 12 |
30 Jun 14 | 2 | -13 | 3 | 11 |
31 Mar 14 | 2 | -12 | 4 | 10 |
31 Dec 13 | 2 | -7 | 4 | 8 |
30 Sep 13 | 2 | -16 | 5 | 15 |
30 Jun 13 | 3 | -20 | 5 | 19 |
Quality Earnings: 3EE0 is currently unprofitable.
Growing Profit Margin: 3EE0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3EE0 is unprofitable, and losses have increased over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare 3EE0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3EE0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: 3EE0 has a negative Return on Equity (-136.14%), as it is currently unprofitable.